Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis

Sodium–glucose cotransporter 2 (SGLT2) inhibitors such as empagliflozin are known to reduce the risk of hospitalizations related to heart failure irrespective of diabetic state. Meanwhile, adverse cardiac remodeling remains the leading cause of heart failure and death in the USA. Thus, understanding...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yang, Huang, Chengqun, Sin, Jon, Germano, Juliana de F., Taylor, David J. R., Thakur, Reetu, Gottlieb, Roberta A., Mentzer, Robert M., Andres, Allen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745294/
https://www.ncbi.nlm.nih.gov/pubmed/35008865
http://dx.doi.org/10.3390/ijms23010437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745294/
https://www.ncbi.nlm.nih.gov/pubmed/35008865
http://dx.doi.org/10.3390/ijms23010437

Ejemplares similares